Prof. Dr. Markus Pietsch
Dr. rer. nat.
Campus Leverkusen
Campusplatz 1
51379 Leverkusen
Raum 2121
Postanschrift
+49 214-32831-4605
markus.pietsch@th-koeln.de
Sprechstunden
Sprechstunde nach Vereinbarung
Campus Leverkusen, Raum 2121
Bitte kontaktieren Sie mich für die Vereinbarung eines Termins (vor Ort oder über Zoom) per E-Mail.
Zoom:
https://th-koeln.zoom-x.de/j/69393933601
Meeting-ID: 693 9393 3601
Kenncode: 004294
Lehrgebiete
- Biochemie und Bioanalytik
- Bio-Pharmazeutische Chemie / Pharmakologie
Forschungsgebiete
-
Entwicklung, Validierung und Optimierung von Assaymethoden zur Untersuchung krankheitsrelevanter Enzyme und Protein-Protein-Wechselwirkungen
-
Expression und Reinigung von Zielproteinen aus prokaryotischen und eukaryotischen Zellen
-
Sceening von Substanzbibliotheken auf biologische Aktivität, molekulare Charakterisierung der Zielstruktur-Ligand-Interaktion, Untersuchungen zu Struktur-Wirkungs-Beziehungen
-
Interaktion niedermolekularer Liganden mit therapeutisch relevanten ProteinenZenrum für Pharmakologie, Uniklinik Köln
Publikationen
-
Contilisant-Belinostat Hybrids: Polyfunctionalized Indole Derivatives as Multineurotarget Drugs for the Potential Treatment of Alzheimer’s DiseaseACS Pharmacology & Translational Science
Schäker-Hübner, L.; Toledano-Pinedo, M.; Eimermacher, S.; Krasniqi, V.; Porro-Pérez, A.; Tan, K.; Horn, G.; Stegen, P.; Elsinghorst, P. W.; Wille, T.; Pietsch, M.; Gütschow, M.; Marco-Contelles, J.; Hansen, F. K., ACS Pharmacol. Transl. Sci. 2025, doi: 10.1021/acsptsci.4c00709, published online ahead of issue on 07. Feb. 2025.
-
Structure–activity relationship studies of tetracyclic pyrrolocarbazoles inhibiting heterotetrameric protein kinase CK2Pubmed
Kröger, L.; Borger, S.; Lauwers, M.; Steinkrüger, M.; Jose, J.; Pietsch, M.; Wünsch, B., Molecules 2025, 30:63, doi: 10.3390/molecules30010063.
-
Photodecarboxylative ring annulation of α- and β-functionalized phthaloyl-GABA derivatives: bioactive pyrroloisoindolinones with high quantum efficiencyChemPhotoChem
Schulze, W.; Zimmer, A.; Neudörfl, J.-M.; Dato, F. M.; Sommerfeld, P.; Pietsch, M.; Derondeau, H.; Gaida, F.; Riedle, E.; Griesbeck, A. G., ChemPhotoChem 2024, 8, e202400033, doi: 10.1002/cptc.202400033.
-
In-depth analysis of Gαs protein activity by probing different fluorescently labeled guanine nucleotidesPubmed
Pepanian, A.; Sommerfeld, P.; Binbay, F. A.; Fischer, D.; Pietsch, M.; Imhof D., Biol. Chem. 2024, 405, 297-309, doi: 10.1515/hsz-2023-0321.
-
Synthesis and evaluation of radioiodinated estrogens for diagnosis and therapy of male urogenital tumours.Pubmed
Braun, F.; Jaschinski, M.; Täger, P.; Marmann, V.; von Brandenstein, M.; Köditz, B.; Fischer, T.; Muñoz-Vázquez, S.; Zimmermanns, B.; Dietlein, M.; Sudbrock, F.; Krapf, P.; Fischer, D.; Heidenreich, A.; Drzezga, A.; Kirsch, S.; Pietsch, M.; Schomäcker, K., Org. Biomol. Chem. 2023, 21, 3090-3095, doi: 10.1039/d3ob00114h.
-
The impact of Nε-acryloyllysine piperazides on the conformational dynamics of transglutaminase 2.Pubmed
Heerwig, A.;# Kick, A.; Sommerfeld P.; # Eimermacher, S.; Hartung, F.; Laube, M.; Fischer, D.; Pietzsch, H.-J.; Pietzsch, J.; Löser, R.; Mertig, M.; Pietsch, M.; Wodtke, R., Int. J. Mol. Sci. 2023, 24:1650. doi: 10.3390/ijms24021650.
# Authors contributed equally to this work. -
Fluorescence anisotropy assay with guanine nucleotides provides access to functional analysis of Gαi1 proteins.Pubmed
Pepanian, A.;# Sommerfeld, P.;# Kasprzyk, R;# Kühl, T.; Binbay, F. A.; Hauser, C.; Löser, R.; Wodtke, R.; Bednarczyk, M.; Chrominski, M.; Kowalska, J.; Jemielity, J.; Imhof, D.; Pietsch, M., Anal. Chem. 2022, 94, 14410-14418. doi: 10.1021/acs.analchem.2c03176.
4th Cover of the issue: https://pubs.acs.org/cms/10.1021/ancham.2022.94.issue-41/asset/ancham.2022.94.issue-41.xlargecover-5.jpg -
Application of a fluorescence anisotropy-based assay to quantify transglutaminase 2 activity in cell lysates.Pubmed
Hauser, S.; Sommerfeld, P.; Wodtke, J.; Hauser, C.; Schlitterlau, P.; Pietzsch, J.; Löser, R.;# Pietsch, M.;#, Wodtke, R.#, Int. J. Mol. Sci. 2022, 23:4475, doi: 10.3390/ijms23094475.
# Authors contributed equally to this work. -
Angiotensin II type 1 receptor localizes at the blood-bile barrier in humans and pigs.Pubmed
Pryymachuk, G.; El-Awaad, E.; Piekarek, N.; Drebber, U.; Maul, A. C.; Hescheler, J.; Wodarz, A.; Pfitzer, G.; Neiss, W. F.; Pietsch, M.; Schroeter, M. M., Histochem. Cell Biol. 2022, 157, 513-524, doi: 10.1007/s00418-022-02087-z.
-
2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors.Pubmed
Schäkel, L.; Mirza, S.; Pietsch, M.; Lee, S.-Y.; Keuler, T.; Sylvester, K.; Pelletier, J.; Sévigny, J.; Pillaiyar, T.; Namasivayam, V.; Gütschow, M.; Müller C. E., Arch. Pharm. (Weinheim) 2021, 354:e2100300, doi: 10.1002/ardp.202100300.
-
Development of an 18F-labeled irreversible inhibitor of transglutaminase 2 as radiometric tool for quantitative expression profiling in cells and tissues.Pubmed
Wodtke, R.: Wodtke, J.; Hauser, S.; Laube, M.; Bauer, D.; Rothe, R.; Neuber, C.; Pietsch, M.; Kopka, K.; Pietzsch, J. Löser, R., J. Med. Chem. 2021, 64, 3462-3478, doi: 10.1021/acs.jmedchem.1c00096.
-
Distinct 3-disulfide-bonded isomers of tridegin differentially inhibit coagulation factor XIIIa: The influence of structural stability on bioactivity.Pubmed
Bäuml, C. A.; Paul George, A. A.; Schmitz, T.; Sommerfeld, P.; Pietsch, M.; Podsiadlowski, L.; Steinmetzer, T.; Biswas, A.; Imhof, D., Eur. J. Med. Chem. 2020, 201:112474, doi: 10.1016/j.ejmech.2020.112474.
-
Synthesis and SAR of tetracyclic inhibitors of protein kinase CK2 derived from furocarbazole W16.Pubmed
Kröger, L.; Daniliuc, C. G.; Ensan, D.; Borgert, S.; Nienberg, C.; Lauwers, M.; Steinkrüger, M.; Jose, J.; Pietsch, M.; Wünsch, B., ChemMedChem 2020, 15, 871-881, doi: 10.1002/cmdc.202000040.
-
Solution-phase synthesis of the fluorogenic TGase 2 acyl donor Z-Glu(HMC)-Gly-OH and its use for inhibitor and amine substrate characterization.Pubmed
Wodtke, R.; Pietsch, M.; Löser, R., Anal. Biochem. 2020, 595:113612, doi: 10.1016/j.ab.2020.113612.
-
Unexpected CK2β-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2.Pubmed
Pietsch, M.; Viht, K.; Schnitzler, A.; Ekambaram, R.; Steinkrüger, M.; Enkvist, E.; Nienberg, C.; Nickelsen, A.; Lauwers, M.; Jose, J.; Uri, A.; Niefind, K., Bioorg. Chem. 2020, 96:103608, doi: 10.1016/j.bioorg.2020.103608.
-
ω-Quinazolinonylalkyl aryl ureas as reversible inhibitors of monoacylglycerol lipase.Pubmed
Dato, F. M.; Neudörfl, J. M.; Gütschow, M.; Goldfuss, B.; Pietsch, M., Bioorg. Chem. 2020, 94:103352, doi: 10.1016/j.bioorg.2019.103352.
-
Direct, gabapentin-insensitive interaction of a soluble form of the calcium channel subunit α2δ-1 with thrombospondin-4.Pubmed
El-Awaad, E.; Pryymachuk, G.; Fried, C.; Matthes, J.; Isensee, J.; Hucho, T.; Neiss, W. F.; Paulsson, M.; Herzig, S.; Zaucke, F.; Pietsch, M., Sci. Rep. 2019, 9:16272, doi: 10.1038/s41598-019-52655-y.
-
Chromenones as Multineurotargeting Inhibitors of Human Enzymes.Pubmed
Lemke, C.; Christmann, J.; Yin, J.; Alonso, J. M.; Serrano, E.; Chioua, M.; Ismaili, L.; Martínez-Grau, M. A.; Beadle, C. D.; Vetman, T.; Dato, F. M.; Bartz, U.; Elsinghorst, P. W.; Pietsch, M.; Müller, C.E.; Iriepa, I.; Wille, T.; et al., ACS Omega 2019, 4, 22161-22168, doi: 10.1021/acsomega.9b03409.
-
AMD-associated HTRA1 variants do not influence TGF-β signaling in microglia. In: Bowes Rickman, C.; Grimm, C.; Anderson, R.; Ash, J.; LaVail, M.; Hollyfield, J. (eds) Retinal Degenerative Diseases.Pubmed
Akhtar-Schaefer, I.; Reuten, R.; Koch, M.; Pietsch, M.; Langmann, T., Adv. Exp. Med. Biol. 2019, 1185, 3-7, doi: 10.1007/978-3-030-27378-1_1.
-
Design of CK2β-mimicking peptides as tools to study the CK2α/CK2β interaction in cancer cells.Pubmed
Lindenblatt, D.; Horn, M.; Götz, C.; Niefind, K.; Neundorf, I.; Pietsch, M., ChemMedChem 2019, 14, 833-841, doi: 10.1002/cmdc.201800786.
-
ω-Phthalimidoalkyl aryl ureas as potent and selective inhibitors of cholesterol esterase.Pubmed
Dato, F. M.; Sheikh, M.; Uhl, R. Z.; Schüller, A. W.; Steinkrüger, M.; Koch, P.; Neudörfl, J.-M.; Gütschow, M.; Goldfuß, B.; Pietsch, M., ChemMedChem 2018, 13, 1833-1847, doi: 10.1002/cmdc.201800388.
-
Crystal structure of highly glycosylated human leukocyte elastase in complex with an S2'-site binding inhibitor.Pubmed
Hochscherf, J.; Pietsch, M.; Tieu, W.; Kuan, K.; Abell, A. D.; Gütschow, M.; Niefind, K., Acta Crystallogr. F Struct. Biol. Commun. 2018, 74, 480-489, doi: 10.1107/S2053230X1800537X.
-
Nԑ-Acryloyllysine piperazides as irreversible inhibitors of transglutaminase 2: Synthesis, structure-activity relationships, and pharmacokinetic profiling.Pubmed
Wodtke, R.; Hauser, C.; Ruiz-Gómez, G.; Jäckel, E.; Bauer, D.; Lohse, M.; Wong, A.; Pufe, J.; Ludwig, F.-A.; Fischer, S.; Hauser, S.; Greif, D.; Pisabarro, M. T.; Pietzsch, J.; Pietsch, M.; Löser, R., J. Med. Chem. 2018, 61, 4528-4560, doi: 10.1021/acs.jmedchem.8b00286.
Cover of the issue: https://pubsapp.acs.org/subscribe/covers/jmcmar/jmcmar_v061i010.jpg?0.4905994756735639=& -
Characterization of fatty acid amide hydrolase activity by a fluorescence-based assay.Pubmed
Dato, F. M.; Maaßen, A.; Goldfuß, B.; Pietsch, M., Anal. Biochem. 2018, 546, 50-57, doi: 10.1016/j.ab.2018.01.026.
-
Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome.Pubmed
Dahlinger, D.; Aslan, S.; Pietsch, M.; Frechen, S.; Fuhr, U., Ther. Adv. Urol. 2017, 9, 163-177, doi: 10.1177/1756287217708951.
-
A fluorescence anisotropy-based assay for determining the activity of tissue transglutaminase.Pubmed
Hauser, C.;* Wodtke, R.;* Löser, R.;# Pietsch, M.#, Amino Acids 2017, 49, 567-583, doi: 10.1007/s00726-016-2192-5.
*, # C. Hauser and R. Wodtke as well as R. Löser and M. Pietsch contributed equally to this work. -
Synthesis and kinetic characterisation of water-soluble fluorogenic acyl donors for transglutaminase 2.Pubmed
Wodtke, R.; Schramm, G.; Pietzsch, J.; Pietsch, M.; Löser, R., ChemBioChem 2016, 17, 1263-1281. Corrigendum: ChemBioChem 2016, 17, 1674, doi: 10.1002/cbic.201600048.
-
Selective inhibitors of glutathione transferase P1 with trioxane structure as anticancer agents.Pubmed
Bräutigam, M.; Teusch, N.; Schenk, T.; Sheikh, M.; Aricioglu, R. Z.; Borowski, S. H.; Neudörfl, J.-M.; Baumann, U.; Griesbeck, A. G.; Pietsch M., ChemMedChem 2015, 10, 629-63, doi: 10.1002/cmdc.201402553.
Back cover of the issue: https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/cmdc.201590010 -
Activated microglia/macrophage whey acidic protein (AMWAP) inhibits NFκB signaling and induces a neuroprotective phenotype in microglia.Pubmed
Aslanidis, A.; Karlstetter, M.; Scholz, R.; Fauser, S.; Neumann, H.; Fried, C.; Pietsch, M.;# Langmann, T.#, J. Neuroinflammation 2015, 12:77, doi: 10.1186/s12974-015-0296-6.
# Authors contributed equally to this work. -
Model studies on peroxidic glutathione transferase (GST) inhibitors: C5-methylated 1,2,4-trioxanes with C6-acrylate side chains.Eur. J. Org. Chem.
Griesbeck, A. G.; Maaßen, A.; Bräutigam, M.; Pietsch, M., Eur. J. Org. Chem. 2015, 4349-4352, doi:10.1002/ejoc.201500326.
Cover of the issue: https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/ejoc.201590054 -
Development of a HTS-compatible assay to identify inhibitors of the CK2a/CK2ß interaction.Pubmed
Hochscherf, J.; Lindenblatt, D.; Steinkrüger, M.; Yoo, E.; Ulucan, Ö.; Herzig, S.; Issinger, O.-G.; Helms, V.; Götz, C.; Neundorf, I.; Niefind, K.; Pietsch, M., Anal. Biochem. 2015, 468, 4-14, doi: 10.1016/j.ab.2014.09.003.
-
Macrocyclic protease inhibitors with reduced peptide character.Pubmed
Chua, K. C.; Pietsch, M.; Zhang, X.; Hautmann, S.; Chan, H. Y.; Bruning, J. B.; Gütschow, M.; Abell, A.D., Angew. Chem. 2014, 126, 7962-7965; Angew. Chem. Int. Ed. 2014, 53, 7828-7831, doi: 10.1002/anie.201404301.
-
Tissue transglutaminase: an emerging target for therapy and imaging.Pubmed
Pietsch, M.; Wodtke, R.; Pietzsch, J.; Löser, R., Bioorg. Med. Chem. Lett. 2013, 23, 6528-6543, doi: 10.1016/j.bmcl.2013.09.060.
Review -
Synthesis and extended activity of triazole-containing macrocyclic protease inhibitors.Pubmed
Pehere, A. D.; Pietsch, M.; Gütschow, M.; Neilsen, P. M.; Callen, D. F.; Pedersen, D. S.; Nguyen, S.; Sykes, M. J.; Zvarec, O.; Abell, A. D., Chem. Eur. J. 2013, 19, 7975-7981, doi: 10.1002/chem.201204260.
-
Regioselective sulfonylation and N- to O-sulfonyl migration of quinazolin-4(3H)-ones and analogous thienopyrimidin-4(3H)-ones.Pubmed
Mertens, M. D.; Pietsch, M.; Schnakenburg, G.; Gütschow, G., J. Org. Chem. 2013, 78, 8966-8979, doi: 10.1021/jo4010876.
-
First structure of protein kinase CK2 catalytic subunit with an effective CK2β-competitive ligand.Pubmed
Raaf, J.; Guerra, B.; Neundorf, I.; Bopp, B.; Issinger, O.-G.; Jose, J.; Pietsch, M.; Niefind, K., ACS Chem. Biol. 2013, 8, 901-907, doi: 10.1021/cb3007133.
-
New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds.Pubmed
Heng, S.; Tieu, W.; Hautmann, S.; Kuan, K.; Pedersen, D. S.; Pietsch, M.; Gütschow, M.; Abell, A. D., Bioorg. Med. Chem. 2011, 19, 7453-7463, doi: 10.1016/j.bmc.2011.10.042.
-
Fluorinated β2- and β3-amino acids: synthesis and inhibition of α-chymotrypsin.Synthesis
Peddie, V.;# Pietsch, M.;# Bromfield, K. M.; Pike, R. N.; Duggan, P. J.; Abell, A. D., Synthesis 2010, 1845-1859, doi: 10.1055/s-0029-1218743.
# Authors contributed equally to this work. -
Calpains: attractive targets for the development of synthetic inhibitors.Pubmed
Pietsch, M.; Chua, K. C. H.; Abell, A. D., Curr. Top. Med. Chem. 2010, 10, 270-293, doi: 10.2174/156802610790725489.
Review -
Isopropylammonium tetrafluorohydrogenphthalate: structural characterization and comparison to two related salts with different stoichiometric ratios.J. Mol. Struct.
Häcker, H.-G.; Schnakenburg, G.; Hoffbauer, W.; Daniels, J.; Pietsch, M.; Gütschow, M., J. Mol. Struct. 2009, 934, 23-27, doi: 10.1016/j.molstruc.2009.06.013.
-
Kinetics of inhibition of acetylcholinesterase in the presence of acetonitrile.Pubmed
Pietsch, M.; Christian, L.; Inhester, T.; Petzold, S.; Gütschow, M., FEBS J. 2009, 276, 2292-2307, doi: 10.1111/j.1742-4658.2009.06957.x.
-
Multiple ligands in opioid research.Pubmed
Ballet, S.; Pietsch, M.; Abell, A. D., Protein Pept. Lett. 2008, 15, 668-682, doi: 10.2174/092986608785133672.
Review -
Structural characterization of two salts derived from tetrafluorophthalic acid and isopropylamine.J. Mol. Struct.
Pietsch, M.; Häcker, H.-G.; Schnakenburg, G.; Hoffbauer, W.; Nieger, M.; Gütschow, M., J. Mol. Struct. 2008, 878, 131-138, doi: 10.1016/j.molstruc.2007.07.044.
-
N-Benzyltetrahydropyrido-anellated thiophene derivatives: new anticholinesterases.Pubmed
Pietsch, M.; Nieger, M.; Gütschow, M., Acta Cryst. 2007, C63, o147-o151, doi: 10.1107/S0108270107001461.
-
Compatible solutes as protectants for zymogens against proteolysis.Pubmed
Kolp, S.; Pietsch, M.; Galinski, E. A.; Gütschow, M., Biochim. Biophys. Acta 2006, 1764, 1234-1242, doi: 10.1016/j.bbapap.2006.04.015.
-
Synthesis of tricyclic 1,3-oxazin-4-ones and kinetic analysis of cholesterol esterase and acetylcholinesterase inhibition.Pubmed
Pietsch, M.; Gütschow, M., J. Med. Chem. 2005, 48, 8270-8288, doi: 10.1021/jm0508639.
-
2,4,5-Triphenylisothiazol-3(2H)-one 1,1-dioxides as inhibitors of human leukocyte elastasePubmed
Gütschow, M.; Pietsch, M.; Themann, A.; Fahrig, J.; Schulze, B., J. Enzyme Inhib. Med. Chem. 2005, 20, 341-347, doi: 10.1080/14756360500148783.
-
Cholesterol esterase action on human high density lipoproteins and inhibition studies: detection by MALDI-TOF MS.Pubmed
Zschörnig, O.; Pietsch, M.; Süß, R.; Schiller, J.; Gütschow, M., J. Lipid Res. 2005, 46, 803-811, doi: 10.1194/jlr.M400265-JLR200.
-
Synthesis of 2-phenylisothiazol-3(2H)-one 1,1 dioxides: inhibitors of human leukocyte elastase.Z. Naturforsch.
Gütschow, M.; Pietsch, M.; Taubert, K.; Freysoldt, T. H. E.; Schulze, B., Z. Naturforsch. 2003, 58b, 111-120, doi: 10.1515/znb-2003-0115.
-
Alternate substrate inhibition of cholesterol esterase by thieno[2,3-d][1,3]oxazin-4-ones.Pubmed
Pietsch, M.; Gütschow, M., J. Biol. Chem. 2002, 277, 24006-24013, doi: 10.1074/jbc.M112252200.
-
Inhibition of cathepsin G by 2-amino-3,1-benzoxazin-4-ones: kinetic investigations and docking studies.Pubmed
Gütschow, M.; Kuerschner, L.; Pietsch, M.; Ambrozak, A.; Neumann, U.; Günther, R.; Hofmann, H.-J., Arch. Biochem. Biophys. 2002, 402, 180-191, doi: 10.1016/S0003-9861(02)00054-1.
-
2-(Diethylamino)thieno[1,3]oxazin-4-ones as stable inhibitors of human leukocyte elastase.Pubmed
Gütschow, M.; Kuerschner, L.; Neumann, U.; Pietsch, M.; Löser, R.; Koglin, N.; Eger, K., J. Med. Chem. 1999, 42, 5437-5447, doi: 10.1021/jm991108w.
-
Patente / PatentsPatente M. Pietsch
Mitgliedschaften
-
Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie e.V. (DGPT)DGPT
Auszeichnungen
-
Rottendorf-Preis für Pharmazie und Pharmakologie 2015, verliehen durch die Rottendorf Pharma GmbH sowie die Rottendorf-Stiftung (15.10.2015)
-
DAAD-Forschungsstipendium (07/2007-06/2008) (PKZ: D/06/48851)
-
Commerzbank-Dissertationspreis 2007 der Rheinischen Friedrich-Wilhelms-Universität Bonn (14.12.2007)
-
PHOENIX-Pharmazie-Wissenschaftspreis 2003 auf dem Gebiet Pharmazeutische Chemie, verliehen durch die PHOENIX Pharmahandel GmbH & Co KG (24.10.2003)
Lebenslauf
seit März 2023 |
Fakultät für Angewandte Naturwissenschaften, TH Köln Professor für Biological Chemistry and Drug Discovery Fakultät für Angewandte Naturwissenschaften, TH Köln |
---|---|
seit März 2010 |
Zentrum für Pharmakologie (früher Institut für Pharmakologie) der Uniklinik Köln (AöR) Projektgruppenleiter (Wissenschaftlicher Mitarbeiter) Zentrum für Pharmakologie, Uniklinik Köln (AöR) |
Juli 2007 - Februar 2010 |
School of Chemistry and Physics (now School of Physics, Chemistry and Earth Sciences), University of Adelaide, Australia Postdoktorand (DAAD Forschungsstipendium (2007-2008), Australian Research Council Associate (2008-2010)) in der Gruppe von Prof. Dr. Andrew D. Abell School of Physics, Chemistry and Earth Sciences, University of Adelaide |
Mai 2006 - Juni 2007 |
Pharmazeutisches Institut, Rheinische Friedrich-Wilhelms-Universität Bonn Postdoktorand in der Gruppe von Prof. Dr. Michael Gütschow Pharmazeutisches Institut, Rheinische Friedrich-Wilhelms-Universität Bonn |
Mai 2001 - April 2006 |
Pharmazeutisches Institut, Rheinische Friedrich-Wilhelms-Universität Bonn Doktorand (Wissenschaftlicher Mitarbeiter); Doktorvater: Prof. Dr. Michael Gütschow; Titel der Dissertation: „Synthese tricyclischer 1,3-Oxazin-4-one und kinetische Analyse der Hemmung der Cholesterolesterase und der Acetylcholinesterase“. 28.04.2006: Promotion zum Dr. rer. nat. in Medizinischer und Pharmazeutischer Chemie. Pharmazeutisches Institut, Rheinische Friedrich-Wilhelms-Universität Bonn |
Oktober 1996 - März 2001 |
Institut für Biochemie, Universität Leipzig Studium der Biochemie; 29.03.2001: Abschluss als Diplom-Biochemiker Institut für Biochemie, Universität Leipzig |